• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices

Alimera Sciences

Alimera Sciences wins Health Canada nod for diabetic macular edema implant

December 5, 2018 By Sarah Faulkner

Alimera Sciences (NSDQ:ALIM) said last month that it won approval in Canada for its intravitreal implant designed to treat diabetic macular edema. The Iluvien device is a sustained release implant that delivers fluocinolone acetonide and is indicated to treat diabetic macular edema in people who have been previously given corticosteroids and did not have a clinically […]

Filed Under: Drug-Device Combinations, Optical/Ophthalmic, Pharmaceutical, Regulatory/Compliance, Wall Street Beat Tagged With: Alimera Sciences, Knight Therapeutics

Alimera, Brill Pharma ink exclusive distribution deal for Iluvien intravitreal implant

March 13, 2017 By Sarah Faulkner

Alimera Sciences (NSDQ:ALIM) said today that it inked an exclusive distribution deal with Spain-based Brill Pharma for its Iluvien sustained-release intravitreal implant. According to the agreement, Brill Pharma will promote, market and commercialize the diabetic macular edema implant in Spain. It will also negotiate with the Spanish Ministry of Health on the implant’s public price and […]

Filed Under: Drug-Device Combinations, Implants, Optical/Ophthalmic, Wall Street Beat Tagged With: Alimera Sciences, Brill Pharma

Alimera, Knight seek Canadian regulatory nod for Iluvien intravitreal implant

February 22, 2017 By Sarah Faulkner

Alimera Sciences (NSDQ:ALIM) and Knight Therapeutics (TSE:GUD) said today that Health Canada accepted the companies’ New Drug Application for its intravitreal implant, Iluvien. The FDA approved Atlanta-based Alimera’s sustained release intravitreal implant in 2014 to treat diabetic macular edema in patients who have been previously treated with corticosteroids and did not have a clinically significant rise […]

Filed Under: Drug-Device Combinations, Implants, Optical/Ophthalmic, Regulatory/Compliance, Wall Street Beat Tagged With: Alimera Sciences, Knight Therapeutics

Alimera surges on buyout rumors

December 17, 2015 By Brad Perriello

(Reuters) — Alimera Sciences (NSDQ:ALIM), an ophthalmic pharmaceutical company, is in the early stages of exploring strategic alternatives, including a potential sale, according to people familiar with the matter. The company has reached out to investment banks to seek advice on how it would be valued in a potential sale and who the likely buyers would be, […]

Filed Under: Drug-Device Combinations, Optical/Ophthalmic, Pharmaceutical, Wall Street Beat Tagged With: Alimera Sciences, pSivida Corp.

Analyst says BSX may take CRM lead | Medtech Wall Street news for the week of September 29, 2014

October 2, 2014 By MassDevice Contributors Network Leave a Comment

Analyst: Boston Scientific could take CRM lead

September 25, 2014 by Alexander Soule

Filed Under: Food & Drug Administration (FDA), News Well, Wall Street Beat Tagged With: Alimera Sciences, Boston Scientific, Echo Therapeutics Inc., Engaged Capital, Leerink Partners, Orthofix, pSivida Corp., stjudemedical, Volcano Corp.

Fourth time’s the charm: pSivida, Alimera jump on FDA nod for Iluvien

September 29, 2014 By Brad Perriello Leave a Comment

Fourth time's the charm: pSivida, Alimera jump on FDA nod for Iluvien

Filed Under: Food & Drug Administration (FDA), News Well, Optical/Ophthalmic, Pre-Market Approval (PMA), Regulatory/Compliance, Wall Street Beat Tagged With: Alimera Sciences, pSivida Corp.

Alimera raises $37.5M in private placement

February 18, 2014 By Arezu Sarvestani Leave a Comment

Alimera raises $37.5M in private placement

Alimera Sciences (NSDQ:ALIM) raised $37.5 million in a recent funding round, planning on using the funds to support general corporate operations.

Filed Under: Drug-Device Combinations, Funding Roundup, News Well, Optical/Ophthalmic Tagged With: Alimera Sciences

pSivida, Alimera Sciences soar as Iluvien skips ahead to FDA review

December 19, 2013 By Arezu Sarvestani Leave a Comment

pSivida soars as copmany skips FDA avisory panel on review path for Iluvien

Filed Under: Food & Drug Administration (FDA), News Well, Optical/Ophthalmic, Pre-Market Approval (PMA) Tagged With: Alimera Sciences, pSivida Corp.

UK regulators OK pSivida’s Iluvien

December 4, 2013 By Chris Walker Leave a Comment

pSivida's Iluvien backed by UK National Health Service

pSivida (NSDQ:PSDV) said the UK’s National Institute for Health & Care Excellence approved its Iluvien drug/device combination.

The approval is for cataract surgery patients who don’t respond to standard treatment for diabetic macular edema, according to a press release.

Filed Under: News Well, Optical/Ophthalmic, Regulatory/Compliance Tagged With: Alimera Sciences, Exports, pSivida Corp.

Third time’s no charm for pSivida, Alimera as FDA again denies Iluvien eye treatment

October 18, 2013 By Arezu Sarvestani Leave a Comment

Third time's no charm for pSivida as FDA again denies Iluvien eye treatment

Filed Under: News Well, Optical/Ophthalmic, Pre-Market Approval (PMA), Regulatory/Compliance Tagged With: Alimera Sciences, pSivida Corp.

Alimera’s Iluvien vision repair implant wins national insurance coverage in France

July 25, 2013 By Sony Salzman Leave a Comment

pSivida
Alimera Sciences

The French National Health Authority granted Alimera Sciences (NSDQ:ALIM) national insurance coverage for the Iluvien vision repair implant, the company said this week.

Filed Under: Drug-Device Combinations, News Well, Optical/Ophthalmic Tagged With: Alimera Sciences, Insurance, pSivida Corp.

  • Page 1
  • Page 2
  • Page 3
  • Go to Next Page »

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy